127 related articles for article (PubMed ID: 35400001)
1. Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Miyata T; Tomita Y; San-Nomiya Y; Nagayama T; Kin R; Nishiki H; Hashimoto A; Fujii Y; Miura S; Kaida D; Nakamura N; Miyashita T; Fujita H; Ueda N; Takamura H
Cancer Diagn Progn; 2022; 2(1):15-24. PubMed ID: 35400001
[TBL] [Abstract][Full Text] [Related]
2. Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Miyata T; Takamura H; Kin R; Nishiki H; Hashimoto A; Fujii Y; Miura S; Fujita J; Kaida D; Tomita Y; Nakamura N; Fujita H; Kinami S; Ueda N; Kosaka T
Anticancer Res; 2020 Jun; 40(6):3361-3370. PubMed ID: 32487632
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Ohta R; Yamada T; Hara K; Iwai T; Tanakaya K; Ishibashi K; Yoshimatsu K; Kosugi C; Tsubaki M; Nakajima H; Oya M; Yoshida H; Koda K; Ishida H
Int J Clin Oncol; 2020 Dec; 25(12):2075-2082. PubMed ID: 32785799
[TBL] [Abstract][Full Text] [Related]
6. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
7. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
8. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin is a novel surrogate marker for oxaliplatin-related sinusoidal obstruction syndrome in patients with colorectal liver metastasis.
Ishii N; Harimoto N; Seki T; Muranushi R; Hagiwara K; Tsukagoshi M; Watanabe A; Yoshida Y; Araki K; Shirabe K
Hepatol Res; 2023 Aug; 53(8):761-770. PubMed ID: 36946410
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
11. Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases.
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
J Int Med Res; 2020 Jun; 48(6):300060520926031. PubMed ID: 32500783
[TBL] [Abstract][Full Text] [Related]
12. Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy.
Eren T; Pasaoglu L
Cureus; 2020 Mar; 12(3):e7230. PubMed ID: 32280572
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin
Kim EJ; Kim M; Seo S; Kim MJ; Kim MJ; Park SR
Anticancer Res; 2021 Jan; 41(1):391-402. PubMed ID: 33419836
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver.
Tajima H; Ohta T; Miyashita T; Nakanuma S; Matoba M; Miyata T; Sakai S; Okamoto K; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Inokuchi M; Nakagawara H; Takamura H; Kitagawa H; Fushida S; Ikeda H
Mol Clin Oncol; 2015 May; 3(3):555-558. PubMed ID: 26137266
[TBL] [Abstract][Full Text] [Related]
15. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity.
Bouferraa Y; Haibe Y; Jabra E; Charafeddine M; Kreidieh M; Raad R; Temraz S; Mukherji D; Ershaid F; Muallem N; Faraj W; Khalife M; Eid RA; Shamseddine A
J Clin Exp Hepatol; 2022; 12(2):448-453. PubMed ID: 35535062
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.
Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG
Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693
[TBL] [Abstract][Full Text] [Related]
18. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
19. Focal Sinusoidal Obstruction Syndrome Caused by Oxaliplatin-Induced Chemotherapy: A Case Report.
Kawai T; Yamazaki S; Iwama A; Higaki T; Sugitani M; Takayama T
Hepat Mon; 2016 Sep; 16(9):e37572. PubMed ID: 27822263
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Iwai T; Yamada T; Koizumi M; Shinji S; Yokoyama Y; Takahashi G; Takeda K; Hara K; Ohta K; Uchida E
J Surg Oncol; 2017 Dec; 116(7):947-953. PubMed ID: 28876454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
